FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients with PSMA Positive mCRPC By Ogkologos - April 25, 2025 552 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAfore study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR The Most Successful Female Singer Of The 1970s Disappeared. Now She’s... May 1, 2019 A Cancer Revolution comes to Manchester: Patrick’s review November 24, 2021 Man Who Lost His Leg Teaches Martial Arts To Orphans Of... December 7, 2021 Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with... November 5, 2025 Load more HOT NEWS Should People With Cancer Be Tested for Hepatitis B? Epcoritamab Shows a Manageable Safety and Robust Antitumour Activity in Heavily... Tesco is making it even easier to support life-saving research Cancer and the Holidays
